Biblio

Export 3 results:
Author Title Type [ Year(Asc)]
Filters: Author is Moebius, Hans J and First Letter Of Keyword is D  [Clear All Filters]
2022
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
2018
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.